Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Newron Pharmaceuticals SpA ( (CH:NWRN) ) has shared an announcement.
Newron Pharmaceuticals announced the presentation of new analyses and updates on their clinical program for Evenamide, an add-on therapy for schizophrenia, at the 38th Congress of the European College of Neuropsychopharmacology. The results from previous studies indicate that Evenamide shows significant clinical benefits for patients with treatment-resistant schizophrenia, offering improvements in symptoms and a favorable safety profile compared to existing treatments. These findings support the initiation of a potentially approval-relevant Phase III study, ENIGMA-TRS 1, which aims to further demonstrate the drug’s efficacy and safety as an add-on therapy for TRS patients.
The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF8.50 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company based in Bresso, near Milan, Italy, focusing on developing novel therapies for central and peripheral nervous system disorders. Their lead drug candidate, Evenamide, is a first-in-class glutamate modulator aimed at treating treatment-resistant schizophrenia (TRS) and patients who respond inadequately to current therapies. The company has a history of successful CNS therapy development, including the Parkinson’s drug Xadago® (Safinamide), and holds licensing agreements for Evenamide in various Asian regions.
Average Trading Volume: 68,719
Technical Sentiment Signal: Buy
Current Market Cap: CHF218.8M
For an in-depth examination of NWRN stock, go to TipRanks’ Overview page.